Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, particularly in innovative drugs, predicting a reversal trend in 2025 [4] Core Viewpoints - The innovative drug sector is experiencing strong performance driven by multiple factors, including the completion of quarterly portfolio adjustments, increased policy support from the National Healthcare Security Administration (NHSA) and the National Health Commission, and significant collaborations in the industry [1][11] - The NHSA and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, which will accelerate the commercialization of domestic innovative products and create a positive cycle of profitability and strong R&D investment [20][21] - The report highlights the potential of dual/multi-target antibodies in cancer treatment and innovative drugs addressing unmet clinical needs in chronic diseases as key investment opportunities [1][4] Summary by Sections Innovative Drugs - The innovative drug sector remains the main investment line, with a focus on dual/multi-target antibodies for various cancers and chronic diseases [1][11] - AstraZeneca is in talks for a collaboration worth up to $15 billion for the AK112 drug, which has catalyzed strong performance in related stocks [1] Pharmaceutical Sector - The NHSA's new measures will direct more healthcare resources towards innovative drugs, enhancing their commercialization and profitability [20][21] - The report notes that since 2018, 149 innovative drugs have been included in the healthcare insurance directory, significantly increasing the proportion of new drugs covered [22] Biologics - Changchun High-tech's new drug, Vuxin Qibai monoclonal antibody, has been approved for treating acute gout arthritis, marking a significant advancement in biologics [29][34] - The drug shows rapid onset of action and a substantial reduction in recurrence risk, highlighting its clinical significance [33][34] Traditional Chinese Medicine - Lingrui Pharmaceutical's new indication for its nasal spray is expected to boost sales, with ongoing efforts to expand hospital coverage and OTC sales [38][41] Medical Devices - The report emphasizes policy support for high-end medical devices, predicting accelerated commercialization in various segments such as medical robots and AI [3][4] Medical Services - Recent policies to enhance maternity benefits are expected to stimulate demand in related services [3][4]

证券分析师 胡琼方 投资咨询资格编号：S1060524010002 2025年7月2日 请务必阅读正文后免责条款 投资要点 1 新一代消费者成长于互联网及移动互联网时代，同时期我国工业制造业蓬勃发展，商品供应逐步充足、信息不对称性快速消弭。新世代 群体注重体验、主打真实、关注自我、个性化等消费偏好驱动出行、零售、美业和宠物等领域变化。 旅游消费潜力持续释放，关注广谱性受益的OTA平台：①国内游：高层多次会议部署促进服务消费，文旅作为其中重要一环近年来持续恢 复，暑期临近，建议关注出行β行情（景区、酒旅等）。②出境游部分预计会受国际环境变化带来的情绪扰动及安全风险影响，入境游 在我国免签政策及美国顶流网红"甲亢哥"中国行带动China Travel流量之下有望进一步增长。个股层面建议关注广谱性受益的OTA平台 企业携程集团-S、同程旅行。 零售回归消费需求本身：①传统零售：社零不同品类表现分化，粮油食品等刚需品及近年来的情绪、文化消费及国货替代品较高速成长。 物质消费整体进入买方市场阶段，线上及线下零售渠道均在回归消费需求本身，零售商/平台扶持优质品牌和商家、优化商品结构、提升 消费体验。建议关注阿里巴巴、永辉 ...

200亿市值医疗器械上市公司，获批医美产品。 据东吴商社吴劲草团队介绍，医美再生注射通常使用生物医用高分子材料作为主要成分，通常以微球形 式注射到真皮层或皮下组织中，从而实现美容和抗衰的目的。 6月3日晚间，国内心血管器械龙头乐普医疗（300003.SZ）发布公告称，公司于今日获悉，自主研发的 聚乳酸面部填充剂获得国家药品监督管理局（NMPA）注册批准。 据介绍，聚乳酸面部填充剂，即"童颜针"，是一种真皮组织填充剂，通过将聚左旋乳酸（PLLA）注射 于真皮深层，起到修复外形，矫正轮廓以达到填充沟壑、皱纹的效果。 公告显示，其主要成分聚左旋乳酸（PLLA）是一种微粒注射型粉末，具有优异的生物相容性、可降解 性和安全性，可在生物体内降解为二氧化碳和水排出体外，不会对人体造成长期影响。 对于此次获批，乐普医疗表示，"产品的成功获批上市是公司在皮肤科领域的重要里程碑事件，标志着 公司正式进入皮肤科领域，进一步助力公司消费医疗事业的健康发展，预计将对公司业务发展产生积极 作用。" 不过，该公司也提示风险称，新产品上市后在推广过程中具体销售情况可能受到包括但不限于临床推 广、渠道开拓、竞争格局改变、宏观政策等因素影响，该 ...

Core Viewpoint - Dongfang Yanmei (Chengdu) Biotechnology Co., Ltd. is facing significant challenges in its attempt to go public on the Hong Kong Stock Exchange, primarily due to long-term losses that exceed revenue and heavy debt burdens [1][2]. Financial Performance - The company reported revenues of RMB 12.88 million and RMB 14.52 million for 2023 and 2024, respectively, while net losses were RMB 63.5 million and RMB 69.38 million, resulting in loss rates of 492% and 478% [2][3]. - The gross margin significantly declined from 11.39% in 2023 to 2.61% in 2024, indicating deteriorating profitability [2]. Product Development and Market Position - The core product, XH301 (poly-L-lactic acid injection), has not yet been approved, with expectations for approval not until the second half of 2025, facing competition from established products in the market [5][7]. - The company has 13 products in the pipeline, but only two are in the registration phase, with the majority still in early development stages, leading to uncertainty in commercialization [3][5]. Customer Dependency - Revenue is heavily reliant on the top five customers, accounting for 55.6% and 52.6% of total revenue in 2023 and 2024, respectively, with the largest customer contributing 32.8% and 18.6% of total revenue [7]. Debt and Financial Health - As of the end of 2024, the company had a debt-to-asset ratio of 123%, with total liabilities reaching RMB 1.93 billion, a 108.27% increase year-on-year [8][9]. - The company reported negative net assets of RMB -0.37 billion by the end of 2024, indicating a precarious financial situation [8][9]. Cash Flow and R&D Expenditure - Cash and cash equivalents were only RMB 33 million at the end of 2024, insufficient to cover R&D expenses of RMB 45.7 million and RMB 45 million for 2023 and 2024, respectively [10]. - The company has defaulted on bank loans totaling RMB 20 million, which could trigger further financial distress [10].

控股股东关联方占用上市公司超过7亿元的资金，能还上吗？爱美客（300896）正在收购韩国REGEN Biotech公司，会不会影响江苏吴中的"童颜针"业务？年报被出具"非标"意见、全资子公司涉嫌骗取出口 退税被起诉、股票被实施退市风险警示及其他风险警示 困境中的江苏吴中如何自救？ 5月21日下午，在*ST苏吴（600200）（SH600200，股价2.81元，市值20亿元，以下简称江苏吴中） 2024年年度股东大会上，公司董事长钱群山和管理层面对多位投资者的"层层拷问"。 对于投资者最为关心的"退市风险"问题，钱群山回应称，目前尚需等待中国证监会的正式调查结论，公 司正积极配合监管部门并和政府部门积极沟通。 他还表示，管理层对公司基本面充满信心，"2024年的经营业绩是我们近5年来最好的，今年的业绩值得 期待，我们新的发展点高端医美也是逆势增长"。 医美业务成为江苏吴中"关键破局点" 年报显示，2024年公司实现营业收入15.99亿元，同比下滑28.64%，其中医药板块收入下降33.19%。不 过，医美业务却实现营收3.30亿元，同比增长逾40倍，占总营收比重快速上升。多位与会股东在交流中 也认为，江苏吴中目 ...

涉嫌信披违法违规被中国证监会立案调查、全资子公司骗取出口退税被起诉、年报被出具"非标"意见、 股票被"披星戴帽"、控股股东关联企业巨额资金占用……今年2月以来，江苏吴中医药发展股份有限公 司（以下简称江苏吴中，股票简称"*ST苏吴（600200）"）负面消息不断。5月14日，江苏吴中发布公 告显示，公司董事长钱群山因涉嫌信息披露违法违规，被中国证监会立案调查。这一消息让深陷困境的 江苏吴中"雪上加霜"，也引发市场对其未来发展的关注。投资者对江苏吴中的信任不断流失，截至5月 15日收盘，江苏吴中的股价已跌至2.38元/股。 屡屡"爆雷"，已走到退市边缘 最新公告中，江苏吴中未披露董事长具体是因何事涉嫌信披违规被立案调查，但称本次立案仅针对董事 长个人，不会对公司日常经营活动产生重大影响。立案调查期间，公司董事长将积极配合中国证监会的 调查工作。 4月22日，江苏吴中披露，公司及全资孙公司江苏吴中医药销售有限公司（简称"吴中销售公司"）因贷 款逾期部分银行账户被冻结。截至公告发布日逾期2095.69万元，被冻结265.11万元。江苏吴中表示，后 续公司银行账户可能存在被进一步冻结的风险。被证监会立案及债务逾期事项 ...

Group 1 - The report highlights a comprehensive set of financial policies aimed at stabilizing the market and expectations, introduced by the National Financial Administration [3][24][26] - The central bank is implementing targeted "leverage" measures to stabilize domestic demand, focusing on technology and consumption as key areas [5][23] - The report emphasizes the importance of supporting technological innovation and the revaluation of technology assets, indicating ongoing policy support for the tech sector [5][24] Group 2 - The report discusses the impact of Trump's first 100 days in office, noting that while tariffs have been a major focus, other areas such as immigration reform have seen more success [4][28] - It predicts a significant decline in GDP due to the effects of tariff policies, with consensus estimates showing a downward adjustment for the first quarter of 2025 [4][29] - The report suggests that upcoming midterm elections will shift focus towards manufacturing repatriation and large-scale tax cuts as key policy priorities [4][33] Group 3 - The report on AI investment opportunities indicates that major tech companies like Microsoft are experiencing significant growth in AI revenue, with a fivefold increase in token processing [9] - It highlights the increasing ROI from AI applications, particularly in advertising, with Meta's AI usage growing significantly [9] - The report suggests that Chinese AI companies are expected to see important investment opportunities with the release of new models, emphasizing the potential for growth in this sector [9][17] Group 4 - The report on TCL Technology outlines its dual leadership in semiconductor displays and photovoltaic silicon, with strong revenue growth projected for the coming years [38][39] - It notes that TCL's proactive cash-based share buyback strategy is expected to enhance earnings and solidify its market position [38][39] - The report anticipates that government subsidy policies will stimulate demand for large-screen TVs, benefiting TCL's sales and market share [39][43] Group 5 - The report on Huayi Brothers indicates a stable revenue growth trajectory, with a focus on expanding its film and television production capabilities [21] - It emphasizes the company's strategic initiatives to enhance its content library and distribution channels, aiming for increased market penetration [21] - The report projects a positive outlook for Huayi Brothers, driven by anticipated growth in the entertainment sector [21]

4月30日，老牌药企江苏吴中医药发展股份有限公司（以下简称：江苏吴中，股票代码：600200.SH） 公布了2024年年度报告及2025年第一季度报告。 年报显示，公司2024年实现营业收入159，851.03万元，实现营业毛利77，258.06万元，同比增加22， 895.16万元，增幅达42.12%，净利润为7，048.35万元。得益于医美业务的显著贡献，公司经营业绩扭 亏为盈，同时也创下近五年新高。 老牌药企布局童颜针 业绩焕发新春 成立于1994年的江苏吴中，先后布局了医药、地产、化工等多个领域。过去几年是江苏吴中面临转型困 境叠加政策转变的困难时期，公司面临诸多经营挑战亏损多年。 公开资料显示，2018年，钱群英通过收购江苏吴中控股股东股权的方式入主上市公司，成为新的实际控 制人。当年江苏吴中出现超2.8亿元的亏损。2019年，因子公司所在化工园区内其他公司发生安全生产 事故，江苏吴中遭遇经营"黑天鹅"。2020年公司亏损超5亿元，2022年和2023年也分别亏损超7000万 元。 2025年一季报显示，江苏吴中医美板块1-3月份营业收入为11，302.25万元，毛利高达9，257.49万元。 相比 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6][17]. Core Views - The company experienced a revenue decline of 17.90% year-over-year in Q1 2025, with total revenue of 663 million yuan and a net profit of 444 million yuan, down 15.87% year-over-year [1]. - The gross margin remained stable at 93.85%, with a slight decrease of 0.70 percentage points year-over-year, while the net profit margin increased by 1.61 percentage points to 66.88% [2]. - The company is pursuing growth through acquisitions and international expansion, notably a planned acquisition of a Korean company for 190 million USD, which is expected to enhance its sales capabilities and open up overseas markets [3]. - The company has a robust pipeline of internal R&D projects, with 11 Class III medical device products already available, and several others in various stages of development, which is expected to support a return to growth [4]. Financial Summary - The company forecasts revenues of 3.29 billion yuan, 3.71 billion yuan, and 4.22 billion yuan for 2025, 2026, and 2027 respectively, with net profits projected at 2.13 billion yuan, 2.40 billion yuan, and 2.73 billion yuan for the same years [4][10]. - The company’s financial metrics indicate a PE ratio of 25x for 2025, decreasing to 20x by 2027, reflecting an expected improvement in profitability [4][10].

今日早参 2025 年 3 月 12 日 何康 策略首席研究员兼金融工程联席首席 研究员 座机：021-28972202 邮箱：hekang@htsc.com 王伟光 策略研究员 邮箱：wangweiguang@htsc.com 张继强 研究所所长、固收首席研究员 座机：13910012450 邮箱：zhangjiqiang@htsc.com 今日热点 策略：资金透视：配置型外资再度净流入 上周两会及产业事件催化 A 股上行，投资者关注其后续演绎方向，我们从资 金层面提供几点观察：1）除杠杆资金外，配置型外资、公募资金是近期资 金面的增量主力，其偏好的基本面因子定价权或有提升；2）配置型外资再 度回暖，A 股&港股作为全球市场的估值洼地，仍具备一定吸引力，关注全 球资金的再配置需求；3）制造及涨价品种近期资金关注度有所提升。 风险提示：1）估算持仓模型失效；2）数据统计口径有误。 研报发布日期：2025-03-11 研究员 何康 SAC:S0570520080004 SFC:BRB318 王伟光 SAC:S0570523040001 固定收益：美股"先破"，谁将"后立"？ 3 月 10 日美国三大股指全线大幅 ...